Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Compare
Compare
Traded in other countries / regions
CPRX.USACN2.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2006-11-08Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 187.85 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 16.34 | |||||
| Beneish M-Score | -2.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 44.4 | |||||
| 3-Year EBITDA Growth Rate | 56.3 | |||||
| 3-Year EPS without NRI Growth Rate | 59 | |||||
| 3-Year FCF Growth Rate | 51.5 | |||||
| 3-Year Book Growth Rate | 44.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.31 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.3 | |||||
| 9-Day RSI | 21.6 | |||||
| 14-Day RSI | 28.8 | |||||
| 3-1 Month Momentum % | 4.35 | |||||
| 6-1 Month Momentum % | 19.6 | |||||
| 12-1 Month Momentum % | 58.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.14 | |||||
| Quick Ratio | 5.96 | |||||
| Cash Ratio | 5.2 | |||||
| Days Inventory | 95.68 | |||||
| Days Sales Outstanding | 42.69 | |||||
| Days Payable | 55.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | 0.01 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.12 | |||||
| Operating Margin % | 43.27 | |||||
| Net Margin % | 36.91 | |||||
| EBITDA Margin % | 50.35 | |||||
| FCF Margin % | 50.05 | |||||
| ROE % | 29.43 | |||||
| ROA % | 25.4 | |||||
| ROIC % | 72.25 | |||||
| 3-Year ROIIC % | 52.43 | |||||
| ROC (Joel Greenblatt) % | 2924.01 | |||||
| ROCE % | 34.27 | |||||
| Years of Profitability over Past 10-Year | 6 | |||||
| Moat score | 4 | |||||
| Tariff score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.66 | |||||
| Forward PE Ratio | 14.69 | |||||
| PE Ratio without NRI | 11.82 | |||||
| Shiller PE Ratio | 59.58 | |||||
| Price-to-Owner-Earnings | 11.97 | |||||
| PEG Ratio | 0.27 | |||||
| PS Ratio | 5.04 | |||||
| PB Ratio | 3.29 | |||||
| Price-to-Tangible-Book | 4.04 | |||||
| Price-to-Free-Cash-Flow | 10.05 | |||||
| Price-to-Operating-Cash-Flow | 10.04 | |||||
| EV-to-EBIT | 8.67 | |||||
| EV-to-Forward-EBIT | 9.1 | |||||
| EV-to-EBITDA | 7.46 | |||||
| EV-to-Revenue | 3.75 | |||||
| EV-to-Forward-Revenue | 3.59 | |||||
| EV-to-FCF | 7.5 | |||||
| Price-to-GF-Value | 0.89 | |||||
| Price-to-Projected-FCF | 1.3 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.47 | |||||
| Price-to-Graham-Number | 1.46 | |||||
| Price-to-Net-Current-Asset-Value | 4.58 | |||||
| Price-to-Net-Cash | 5.62 | |||||
| Earnings Yield (Greenblatt) % | 11.53 | |||||
| FCF Yield % | 10.23 | |||||
| Forward Rate of Return (Yacktman) % | 24.42 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers